Efficacy generated by afatinib in a lung adenocarcinoma patient harboring HER2 S310Y mutation

References

• Shigematsu H, Takahashi T, Nomura M, Majmudar K, Suzuki M, Lee H, Wistuba II, Fong KM, Toyooka S, Shimizu N, et al. Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res. 2005;65:1642–6. doi:10.1158/0008-5472.CAN-04-4235. PMID:15753357.
   PubMed Web of Science ®Google Scholar
• Arcila ME, Chaft JE, Nafa K, Roy-Chowdhuri S, Lau C, Zaidinski M, Paik PK, Zakowski MF, Kris MG, Ladanyi M. Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas. Clin Cancer Res. 2012;18:4910–8. doi:10.1158/1078-0432.CCR-12-0912. PMID:22761469.
   PubMed Web of Science ®Google Scholar
• Solca F, Dahl G, Zoephel A, Bader G, Sanderson M, Klein C, Kraemer O, Himmelsbach F, Haaksma E, Adolf GR. Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. J Pharmacol Exp Ther. 2012;343:342–50. doi:10.1124/jpet.112.197756. PMID:22888144.
   PubMed Web of Science ®Google Scholar
• Peters S, Zimmermann S. Targeted therapy in NSCLC driven by HER2 insertions. Transl Lung Cancer Res. 2014;3:84–8. PMID:25806285.
   PubMedGoogle Scholar
• Chang MT, Asthana S, Gao SP, Lee BH, Chapman JS, Kandoth C, Gao J, Socci ND, Solit DB, Olshen AB, et al. Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. Nat Biotechnol. 2016;34:155–63. doi:10.1038/nbt.3391. PMID:26619011.
   PubMed Web of Science ®Google Scholar
• Kan Z, Jaiswal BS, Stinson J, Janakiraman V, Bhatt D, Stern HM, Yue P, Haverty PM, Bourgon R, Zheng J, et al. Diverse somatic mutation patterns and pathway alterations in human cancers. Nature. 2010;466:869–73. doi:10.1038/nature09208. PMID:20668451.
   PubMed Web of Science ®Google Scholar
• Greulich H, Kaplan B, Mertins P, Chen TH, Tanaka KE, Yun CH, Zhang X, Lee SH, Cho J, Ambrogio L, et al. Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2. Proc Natl Acad Sci U S A. 2012;109:14476–81. doi:10.1073/pnas.1203201109. PMID:22908275.
   PubMed Web of Science ®Google Scholar
• Moasser MM. The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene. 2007;26:6469–87. doi:10.1038/sj.onc.1210477. PMID:17471238.
   PubMed Web of Science ®Google Scholar
• Genova C, Rijavec E, Barletta G, Burrafato G, Biello F, Dal Bello MG, Coco S, Truini A, Alama A, Boccardo F, et al. Afatinib for the treatment of advanced non-small-cell lung cancer. Expert Opin Pharmacother. 2014;15:889–903. doi:10.1517/14656566.2014.902445. PMID:24646054.
   PubMed Web of Science ®Google Scholar
• Hurwitz JL, Scullin P, Campbell L. Afatinib treatment in advanced non-small cell lung cancer. Lung Cancer (Auckl). 2011;2:47–57. PMID:28210118.
   PubMedGoogle Scholar
• Keating GM. Afatinib: a review of its use in the treatment of advanced non-small cell lung cancer. Drugs. 2014;74:207–21. doi:10.1007/s40265-013-0170-8. PMID:24435321.
   PubMed Web of Science ®Google Scholar
• Geuna E, Montemurro F, Aglietta M, Valabrega G. Potential of afatinib in the treatment of patients with HER2-positive breast cancer. Breast Cancer (Dove Med Press). 2012;4:131–7. PMID:24367201.
   PubMedGoogle Scholar
• Kris MG, Camidge DR, Giaccone G, Hida T, Li BT, O'Connell J, Taylor I, Zhang H, Arcila ME, Goldberg Z, et al. Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors. Ann Oncol. 2015;26:1421–7. doi:10.1093/annonc/mdv186. PMID:25899785.
   PubMed Web of Science ®Google Scholar
• Arcila ME, Nafa K, Chaft JE, Rekhtman N, Lau C, Reva BA, Zakowski MF, Kris MG, Ladanyi M. EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics. Mol Cancer Ther. 2013;12:220–9. doi:10.1158/1535-7163.MCT-12-0620. PMID:23371856.
   PubMed Web of Science ®Google Scholar
• Herter-Sprie GS, Greulich H, Wong KK. Activating mutations in ERBB2 and their impact on diagnostics and treatment. Front Oncol. 2013;3:86. doi:10.3389/fonc.2013.00086. PMID:23630663.
   PubMedGoogle Scholar
• Li BT, Lee A, O'Toole S, Cooper W, Yu B, Chaft JE, Arcila ME, Kris MG, Pavlakis N. HER2 insertion YVMA mutant lung cancer: Long natural history and response to afatinib. Lung Cancer. 2015;90:617–9. doi:10.1016/j.lungcan.2015.10.025. PMID:26559459.
   PubMed Web of Science ®Google Scholar
• Jasra S, Opyrchal M, Norton L, Mehta R. A Rare Case of S310F Somatic ERBB2 Mutation in a HER2-Nonamplified Breast Cancer. Clin Breast Cancer. 2017;17:e37–41. doi:10.1016/j.clbc.2016.08.001. PMID:27665021.
   PubMed Web of Science ®Google Scholar
• Vornicova O, Hershkovitz D, Yablonski-Peretz T, Ben-Itzhak O, Keidar Z, Bar-Sela G. Treatment of metastatic extramammary Paget's disease associated with adnexal adenocarcinoma, with anti-HER2 drugs based on genomic alteration ERBB2 S310F. Oncologist. 2014;19:1006–7. doi:10.1634/theoncologist.2014-0054. PMID:25085898.
   PubMed Web of Science ®Google Scholar
• Li BT, Ross DS, Aisner DL, Chaft JE, Hsu M, Kako SL, Kris MG, Varella-Garcia M, Arcila ME. HER2 Amplification and HER2 mutation are distinct molecular targets in lung cancers. J Thorac Oncol. 2016;11:414–9. doi:10.1016/j.jtho.2015.10.025. PMID:26723242.
   PubMed Web of Science ®Google Scholar
• Li C, Sun Y, Fang R, Han X, Luo X, Wang R, Pan Y, Hu H, Zhang Y, Pao W, et al. Lung adenocarcinomas with HER2-activating mutations are associated with distinct clinical features and HER2/EGFR copy number gains. J Thorac Oncol. 2012;7:85–9. doi:10.1097/JTO.0b013e318234f0a2. PMID:22071781.
   PubMed Web of Science ®Google Scholar
• Mazieres J, Peters S, Lepage B, Cortot AB, Barlesi F, Beau-Faller M, Besse B, Blons H, Mansuet-Lupo A, Urban T, et al. Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. J Clin Oncol. 2013;31:1997–2003. doi:10.1200/JCO.2012.45.6095. PMID:23610105.
   PubMed Web of Science ®Google Scholar
• Yoshizawa A, Sumiyoshi S, Sonobe M, Kobayashi M, Uehara T, Fujimoto M, Tsuruyama T, Date H, Haga H. HER2 status in lung adenocarcinoma: a comparison of immunohistochemistry, fluorescence in situ hybridization (FISH), dual-ISH, and gene mutations. Lung Cancer. 2014;85:373–8. doi:10.1016/j.lungcan.2014.06.007. PMID:25047676.
   PubMed Web of Science ®Google Scholar